1Ahn YS, Byrnes JJ, Harrington WJ, et al. The treatment of idiopathic thrombocytopenia with vinblastine-loaded platelets[J].N Engl J Med, 1978,298(20):1101 ～ 1107.
2Debili N, Wendling F, Katz A, et al. The Mpl-ligand or thrombopoietin or megakaryocyte growth and differentiative factor has both direct proliferative and differentiative activities on human megakaryocyte progenitors [J]. Blood, 1995,86 (7): 2516～ 2525.
3Banu N, Wang JF, Deng B, et al. Modulation of megakaryocytopoiesis by thrombopoietin: the c-Mpl ligand [J]. Blood,1995,86(4): 1331 ～ 1338.
6Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? [J].Control Clin Trials, 1996,17 (1) : 1.
8Chang M, Nakagawa PA, Williams SA, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryoeytopoiesis in vitro[J]. Blood, 2003,102 (3) :887.
9Cremer M, Schulze H, Linthorst G, et al. Serum levels of thrombopoietin, IL-11, and IL-6 in pediatric thrombocytopenias[J]. Ann Hematol, 1999,78 ( 9 ) : 401.
10Wendling F, Maraskovsky E, Debili N, et al. cMpl ligand is a humoral regulator of megakaryocytopoiesis[J]. Nature, 1994,369(6 481) : 571.
